AzTrials
AzTrials

AsthmaPhase 3RAINBOWNCT00384189

A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma

A Phase 3 study testing Ciclesonide and Salbutamol in people with Asthma, run by AstraZeneca at 122 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Read more about this study

Who is it for?
Ages 6 to 11 years
Conditions the study is for
Asthma
What is being tested?
Ciclesonide and Salbutamol
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,080 participants
Where
122 sitesin 9 countries
Study dates
Sep 2006to Aug 2008
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 11 years
  • All sexes
  • No healthy volunteers
  • Child

Main Inclusion Criteria:

  • History of asthma for at least 6 months
  • Ability to show optimal use of MDI, including inhalation technique
  • Lung function and reversibility within specified limits

Main Exclusion Criteria:

  • Concomitant severe diseases
  • Diseases which are contraindications for the use of inhaled steroids
  • Two or more inpatient hospitalizations for asthma within the last year
  • Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study
  • Use of systemic steroids within the last 30 days prior to inclusion (depot steroids 6 weeks)
  • Beginning of or change in immunotherapy within the last 6 months prior to inclusion
  • Inability to follow the procedures of the study

Trial locations and contacts

122 sites in 9 countries.

122 sites in 9 countries

Russia32 sites
  • Altana Pharma/Nycomed

    Chelyabinsk

  • Altana Pharma/Nycomed

    Ivanovo

  • Altana Pharma/Nycomed

    Kislovodsk, 357703

  • Altana Pharma/Nycomed

    Moscow, 105077

  • Altana Pharma/Nycomed

    Moscow, 115446

  • Altana Pharma/Nycomed

    Moscow, 115478

  • Altana Pharma/Nycomed

    Moscow, 117513

  • Altana Pharma/Nycomed

    Moscow, 119049

  • Altana Pharma/Nycomed

    Moscow, 119526

  • Altana Pharma/Nycomed

    Moscow, 119991

  • Altana Pharma/Nycomed

    Moscow, 125412

  • Altana Pharma/Nycomed

    Moscow, 129090

  • Altana Pharma/Nycomed

    Moscow

  • Altana Pharma/Nycomed

    Murmansk, 183047

  • Altana Pharma/Nycomed

    Novosibirsk, 630091

  • Altana Pharma/Nycomed

    Rostov-on-Don, 1344068

  • Altana Pharma/Nycomed

    Saint Petersburg, 191036

  • Altana Pharma/Nycomed

    Saint Petersburg, 191123

  • Altana Pharma/Nycomed

    Saint Petersburg, 192212

  • Altana Pharma/Nycomed

    Saint Petersburg, 193144

  • Altana Pharma/Nycomed

    Saint Petersburg, 194100

  • Altana Pharma/Nycomed

    Saint Petersburg, 194156

  • Altana Pharma/Nycomed

    Saint Petersburg, 196084

  • Altana Pharma/Nycomed

    Saint Petersburg, 196650

  • Altana Pharma/Nycomed

    Saint Petersburg, 198205

  • Altana Pharma/Nycomed

    Saint Petersburg, 199053

  • Altana Pharma/Nycomed

    Saint Petersburg

  • Altana Pharma/Nycomed

    Samara, 443000

  • Altana Pharma/Nycomed

    Smolensk

  • Altana Pharma/Nycomed

    Tomsk

  • Altana Pharma/Nycomed

    Vladimir

  • Altana Pharma/Nycomed

    Voronezh

Other trials in Russia

South Africa14 sites
  • Altana Pharma/Nycomed

    Bellville - Cape Town -, 7530

  • Altana Pharma/Nycomed

    Bloemfontein, 9301

  • Altana Pharma/Nycomed

    Cape Town, 7937

  • Altana Pharma/Nycomed

    Centurion, 157

  • Altana Pharma/Nycomed

    Durban, 3630

  • Altana Pharma/Nycomed

    Durban, Amanzimtoti, 4126

  • Altana Pharma/Nycomed

    Gezina, Pretoria, 84

  • Altana Pharma/Nycomed

    Morningside, Sandton, 2196

  • Altana Pharma/Nycomed

    Mowbray, Cape Town, 7925

  • Altana Pharma/Nycomed

    New Redruth, Alberton, 1450

  • Altana Pharma/Nycomed

    Panorama / RSA-Cape Town, 7500

  • Altana Pharma/Nycomed

    Somerset West, 7130

  • Altana Pharma/Nycomed

    Westville, 3630

  • Altana Pharma/Nycomed

    Wynberg, 7945

Other trials in South Africa

Ukraine14 sites
  • Altana Pharma/Nycomed

    Dnipropetrovsk, 49101

  • Altana Pharma/Nycomed

    Donetsk, 83017

  • Altana Pharma/Nycomed

    Donetsk, 83045

  • Altana Pharma/Nycomed

    Kharkiv, 61051

  • Altana Pharma/Nycomed

    Kiev, 3680

  • Altana Pharma/Nycomed

    Kyiv, 1135

  • Altana Pharma/Nycomed

    Kyiv, 2125

  • Altana Pharma/Nycomed

    Kyiv, 4050

  • Altana Pharma/Nycomed

    Lviv, 79059

  • Altana Pharma/Nycomed

    Odesa, 65031

  • Altana Pharma/Nycomed

    Poltava, 36011

  • Altana Pharma/Nycomed

    Simferopol, 95004

  • Altana Pharma/Nycomed

    Vinnytsia

  • Altana Pharma/Nycomed

    Zaporizhzhya, 69063

Other trials in Ukraine

Germany13 sites
  • Altana Pharma/Nycomed

    Dresden, 1067

  • Altana Pharma/Nycomed

    Freising, 85354

  • Altana Pharma/Nycomed

    Fulda, 36039

  • Altana Pharma/Nycomed

    Homburg, 66424

  • Altana Pharma/Nycomed

    Kassel, 34121

  • Altana Pharma/Nycomed

    Leipzig, 4207

  • Altana Pharma/Nycomed

    Mannheim, 68167

  • Altana Pharma/Nycomed

    Marburg, 35037

  • Altana Pharma/Nycomed

    München, 80939

  • Altana Pharma/Nycomed

    Rosenheim, 83026

  • Altana Pharma/Nycomed

    Schwäbisch Hall, 74523

  • Altana Pharma/Nycomed

    Welzheim, 73642

  • Altana Pharma/Nycomed

    Wesel, 46483

Other trials in Germany

Romania13 sites
  • Altana Pharma/Nycomed

    Brasov, 500063

  • Altana Pharma/Nycomed

    Bucharest, 11025

  • Altana Pharma/Nycomed

    Bucharest, 11743

  • Altana Pharma/Nycomed

    Bucharest, 20395

  • Altana Pharma/Nycomed

    Bucharest, 22102

  • Altana Pharma/Nycomed

    Bucharest, 22444

  • Altana Pharma/Nycomed

    Bucharest, 41451

  • Altana Pharma/Nycomed

    Cluj-Napoca, 400217

  • Altana Pharma/Nycomed

    Cluj-Napoca, 400371

  • Altana Pharma/Nycomed

    Craiova, 200341

  • Altana Pharma/Nycomed

    Galati, 800487

  • Altana Pharma/Nycomed

    Iași, 700309

  • Altana Pharma/Nycomed

    Sibiu, 550166

Other trials in Romania

Spain12 sites
  • Altana Pharma/Nycomed

    Barcelona, 8003

  • Altana Pharma/Nycomed

    Barcelona, 8035

  • Altana Pharma/Nycomed

    Barcelona, 8222

  • Altana Pharma/Nycomed

    Esplugues de Llobregat, 8950

  • Altana Pharma/Nycomed

    Leganés, 28911

  • Altana Pharma/Nycomed

    Madrid, 28006

  • Altana Pharma/Nycomed

    Madrid, 28009

  • Altana Pharma/Nycomed

    Madrid, 28040

  • Altana Pharma/Nycomed

    Madrid, 28041

  • Altana Pharma/Nycomed

    Manresa, 8240

  • Altana Pharma/Nycomed

    Sabadell (Barcelona), 8208

  • Altana Pharma/Nycomed

    Tarrasa, 8211

Other trials in Spain

Hungary10 sites
  • Altana Pharma/Nycomed

    Budapest, 1089

  • Altana Pharma/Nycomed

    Budapest, 1121

  • Altana Pharma/Nycomed

    Debrecen, 4012

  • Altana Pharma/Nycomed

    Jászberény, 5100

  • Altana Pharma/Nycomed

    Kiskunhalas, 6400

  • Altana Pharma/Nycomed

    Miskolc, 3501

  • Altana Pharma/Nycomed

    Mosdós, 7257

  • Altana Pharma/Nycomed

    Mosonmagyaróvár, 9200

  • Altana Pharma/Nycomed

    Pécs, 7624

  • Altana Pharma/Nycomed

    Szeged, 6720

Other trials in Hungary

Poland9 sites
  • Altana Pharma/Nycomed

    Inowrocław, 88-100

  • Altana Pharma/Nycomed

    Lodz, 90-141

  • Altana Pharma/Nycomed

    Lodz, 93-513

  • Altana Pharma/Nycomed

    Lublin, 20-093

  • Altana Pharma/Nycomed

    Poznan, 60-693

  • Altana Pharma/Nycomed

    Torun, 87-100

  • Altana Pharma/Nycomed

    Warsaw, 01-211

  • Altana Pharma/Nycomed

    Warsaw, 03-924

  • Altana Pharma/Nycomed

    Zawadzkie, 46-059

Other trials in Poland

Bulgaria5 sites
  • Altana Pharma/Nycomed

    Plovdiv, 4000

  • Altana Pharma/Nycomed

    Plovdiv, 4002

  • Altana Pharma/Nycomed

    Rousse, 7004

  • Altana Pharma/Nycomed

    Sofia, 1431

  • Altana Pharma/Nycomed

    Vama, 9010

Other trials in Bulgaria

About this study

Official title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma

The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.

Read the detailed description

The drug being tested is called ciclesonide. This study looked at the safety and efficacy of inhaled ciclesonide in children with asthma. The study enrolled 1080 patients.

Participants were randomly assigned to 1 of 4 treatment groups which were undisclosed to the patient and study doctor during the study:• Ciclesonide 40 µg, 80 µg or 160 µg • Placebo- this is similar to study drug but has no active ingredient. Ciclesonide was inhaled via a metered-dose inhaler (MDI with HFA-134a propellant), with or without spacer, once daily in the evening throughout the study. All participants were asked to document daily AM and PM peak expiratory flow (PEF), daytime and nighttime asthma symptom scores and number of puffs of rescue medicine in an electronic diary. This multi-centre trial was conducted worldwide. The overall time to participate in this study was 20 weeks. Participants made multiple visits to the clinic plus a final visit 30 days after the last dose of study drug for a follow-up assessment.

Conditions
Asthma
Being tested
Ciclesonide, Placebo, Salbutamol
Keywords
Asthma, Ciclesonide, children
Medical subject headings
Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CiclesonideDrug

    inhaled Ciclesonide

  • PlaceboDrug

    Ciclesonide placebo-matching inhaler

  • SalbutamolDrug

    Salbutamol inhalation powder

Study groups in NCT00384189
Study groupRoleWhat they receive
Ciclesonide 40 µgActive comparatorPlacebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
Receives: Drug: Ciclesonide; Drug: Placebo; Drug: Salbutamol
Ciclesonide 80 µgActive comparatorPlacebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
Receives: Drug: Ciclesonide; Drug: Placebo; Drug: Salbutamol
Ciclesonide 160 µgActive comparatorPlacebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
Receives: Drug: Ciclesonide; Drug: Placebo; Drug: Salbutamol
PlaceboPlacebo comparatorPlacebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
Receives: Drug: Placebo; Drug: Salbutamol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Morning Peak Expiratory Flow (PEF)

    PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis. Last observation carried forward.

    Measured: Baseline and Week 12

Secondary outcomes (12)
  1. Time to First Event of Lack of Efficacy (LOE) by Week 12

    Kaplan Meier Estimates of the probability of not experiencing LOE by Week 12 was measured. LOE was reached if any of the following criteria occurred during the treatment period: • asthma exacerbation (a worsening of asthma symptoms requiring a change in medication; • nocturnal awakenings due to asthma on any 4 or more nights during any 7-consecutive-day period; • use of more than 8 puffs/day of salbutamol on any 4 or more days during any 7-consecutive-day period; • decrease in morning PEF to <80% of randomization value on any 4 consecutive days during the treatment period.

    Measured: 12 weeks

  2. Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication, Morning PEF and PEF Fluctuation

    Control of asthma was evaluated on a daily basis (24 hours) using the following variables: asthma symptoms, use of rescue medication, morning (am) PEF and PEF fluctuation. The median percentage of days with asthma control is presented.

    Measured: 28 days prior to last visit (Up to 12 Weeks)

  3. Change From Baseline in Lung Function Variable Forced Expiratory Volume in One Second (FEV1)

    Spirometry was performed according to local standards. FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Higher change numbers indicate better lung function.

    Measured: Baseline and Week 12

  4. Change From Baseline in Lung Function Variable PEF by Spirometry

    Spirometry was performed according to local standards. PEF is the maximum speed of expiration. Analysis was ANCOVA with factors value at Baseline, treatment, age, sex, center pool, ICS pretreatment, spacer use and asthma severity. Higher change numbers indicate better lung function.

    Measured: Baseline and Week 12

  5. Change From Baseline in Morning PEF From Diary

    PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.

    Measured: Baseline and Weeks 1 thru 12

  6. Change From Baseline in Evening PEF From Diary

    PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.

    Measured: Baseline and Week 12

  7. Change From Baseline in Diurnal PEF Fluctuations

    PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. A negative change from Baseline indicates improvement. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.

    Measured: Baseline and Week 12

  8. Change in Asthma Symptom Total Score

    Measurements of both nighttime and daytime asthma symptoms were assessed on a daily basis by the patient in the electronic diary, according to the following scales: Nighttime Asthma Score using a 5 point scale: 0=no asthma symptoms, slept through the night to 4=bad night, awake most of the night because of asthma. Daytime Asthma Score using a 5 point scale: 0=very well, no asthma symptoms to 4=asthma very bad, unable to carry out daily activities as usual. Total possible overall daily score range from 0(best) to 4 (worst). A negative change from Baseline indicated improvement.

    Measured: Baseline and Week 12

  9. Change in Use of Rescue Medications

    The daily use of rescue medication (salbutamol) was recorded in the electronic diary in the morning and the evening. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 12

  10. Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication and Morning PEF

    Control of asthma was evaluated on a daily basis (24 hours) using the following variables: asthma symptoms, use of rescue medication, and morning (am) PEF. The median percentage of days with asthma control is presented.

    Measured: 28 days prior to last visit (Up to 12 Weeks)

  11. Change From Baseline in Pediatric Asthma Quality of Life Questionnaire Standard [PAQLQ(S)] Overall Score

    PAQLQS is a disease specific instrument to assess the impact of asthma on the patient's quality of life. The PAQLQS consists of 23 items in 3 domains evaluating activity limitations, symptoms and emotional function. Patients answered each question using a 7-point scale from 1= maximum impairment to 7=no impairment) about their experience during the previous week. Total possible score ranging from 23 (worst) to 161(best). Higher change from Baseline scores are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis.

    Measured: Baseline and Week 12

  12. Change From Baseline in Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) Overall

    PACQLQ assesses the impact of the child's asthma on the quality of life of the caregiver. The PACQLQ consists of 13 items in 2 domains evaluating activity limitations and emotional function. Caregivers answered each question using a 7-point scale from 1= maximum impairment to 7=no impairment about their experience during the previous week. Total possible score ranging from 13 (worst) to 91(best). Higher change from Baseline scores are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis.

    Measured: Baseline and Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2006 (estimated)
  2. Study startSep 2006
  3. Primary completionAug 2007
  4. Study completionAug 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
1,080 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00384189
Sponsor's protocol ID
BY9010/M1-209
Other IDs
U1111-1172-2297
Acronym
RAINBOW
Status last verified
Oct 2016
First submitted
4 Oct 2006
Last updated
1 Feb 2017
Data monitoring committee
No

Publications

  • Pedersen S, Potter P, Dachev S, Bosheva M, Kaczmarek J, Springer E, Dunkel J, Engelstatter R. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study. Respir Med. 2010 Nov;104(11):1618-28. doi: 10.1016/j.rmed.2010.06.012. Epub 2010 Jul 8.

    PubMed 20619624

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ciclesonide and Salbutamol in people with Asthma, run by AstraZeneca at 122 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 122 sites in Russia, South Africa, Ukraine, Germany, Romania and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Aug 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Morning Peak Expiratory Flow (PEF) (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00384189, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in